Healthcare Shake‑Up: Time to Cut Thermo Fisher and Chase Lilly’s Momentum?

TMO’s slide killed the momentum, so Bill Baruch rotated out and into LLY’s breakout strength. He’s betting LLY earnings surge can fuel a run through June. Watch the full discussion here.

Share

Latest Insights

Our team at Blue Line Capital, led by founder Bill Baruch, shares their expertise and unique market perspective.
Bill Baruch has outlined his checklist prior to Nvidia's report, focusing on initial Rubin deliveries, Blackwell efficiencies, margins, and memory costs. He is particularly interested in management's comments on the financing deal and anticipates potential positive surprises from the non-GPU business, AI models, and CPU products.